Literature DB >> 8182001

Administering amphotericin B--a practical approach.

S H Khoo1, J Bond, D W Denning.   

Abstract

Despite the introduction in recent years of novel antifungal agents, the potency and broad spectrum of activity of amphotericin B have ensured that it remains the treatment of choice for most deep-seated mycoses. However, this agent is not without significant toxicity, particularly in patients who are already seriously ill and/or who are receiving other potentially nephrotoxic drugs. We review the various routes by which amphotericin B can be administered, focusing mainly on the intravenous route. The use of more rapid infusion rates, lipid-complexed preparations, sodium supplementation in salt-depleted patients and strategies to reduce the incidence of infusion-related reactions and nephrotoxicity are also considered. Finally, detailed recommendations for the administration of amphotericin B are provided.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182001     DOI: 10.1093/jac/33.2.203

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  33 in total

1.  Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion.

Authors:  B Beović; T Lejko-Zupanc; J Pretnar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

2.  In search of the amazing technicolour dream coat for amphotericin B.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-07

3.  Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

4.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

5.  Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Authors:  Chandeshwar P Thakur; A Kumar; Dipendra K Mitra; Ambak Roy; Arun Kumar Sinha; Alok Ranjan
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

6.  Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

Authors:  Samusi A Adediran; Timothy P Day; Diptesh Sil; Matthew R Kimbrell; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

7.  Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.

Authors:  S Walker; S A Tailor; M Lee; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 9.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

10.  Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.

Authors:  Daoud Al-Badriyeh; Chin Fen Neoh; Kay Stewart; David C M Kong
Journal:  Clin Ophthalmol       Date:  2010-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.